On June 5, 2026, South Africa officially launched lenacapavir, a twice‑annual injectable pre‑exposure prophylaxis, in the mining town of Secunda. President Cyril Ramaphosa, Health Minister Aaron Motsoaledi and local health workers presented the drug as a solution to low adherence rates of daily oral pills, especially among young people.

Lenacapavir’s twice‑yearly dosing aims to boost adherence

According to the launch briefing, the injection is given every six months, a schedule that health officials say will reduce missed doses caused by stigma,forgetfulness, or side effects. nurses demonstrated the pre‑filled syringes and explained that the simple procedure can be performed in mobile clinics, allowing rapid rollout to remote villages and urban townships.

Mobile clinics will deliver the shot free of charge

The programme will use mobile units to travel across Mpumalanga, offering the injection at no cost while providing sexual‑health counseling.. Health Minister Aaron Motsoaledi emphasized that the free service is part of a broader strategy to curb new infections and free up staff for testing and treatment adherence.

Youth trial participants share hope for a generation‑saving tool

Olwam Plaatjie,a former trial volunteer, told reporters that watchinng family members suffer from HIV drove her to seek a more reliable preventive option. She said the three‑year trial left her feeling empowered and hopeful that lenacapavir could spare her peers from the disease.

International partners back South Africa’s rollout

As reported by officials, the Global Fund and several research institutions have pledged financial and technical support to scale the initiative nationwide. if the South African model proves successful, other high‑prevalence natios may adopt the biannual injection as a pragmatic prevention strategy.

Key unanswered questions about long‑term effectiveness

What remains unclear is how long‑term protection will hold up in real‑world settings and whether resistance could emerge with widespread use. The source did not provide data on post‑launch infection rates, leaving analysts to watch early outcomes closely.